Cencora Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.87%.
Did COR Beat Earnings? Q2 2025 Results
Cencora posted a solid fiscal second quarter, beating profit expectations comfortably while falling just short on the top line, as surging demand for specialty pharmaceuticals and GLP-1 products continued to power the business forward. Adjusted diluted EPS came in at $4.42, beating the $4.10 consensus estimate by 7.92% and rising 16.3% from the prior year, while revenue climbed 10.3% year-over-year to $75.45 billion, a fraction below the $75.80 billion analysts had expected. The U.S. Healthcare Solutions segment was the clear engine of growth, expanding 11.4% on the strength of specialty drug volumes, while the International segment offered little help, with operating income slipping 17.3% to $159.30 million amid weakness in global specialty logistics. The January acquisition of Retina Consultants of America, financed with roughly $3.30 billion in new debt, added meaningful gross profit contribution even as it had limited near-term revenue impact due to intercompany eliminations. Encouraged by U.S. earnings momentum, Cencora raised its full-year adjusted diluted EPS guidance to $15.70 to $15.95, up from $15.30 to $15.60 previously.
- Unit volume growth in overall pharmaceutical distribution market
- Increased sales of GLP-1 class products labeled for diabetes and/or weight loss
- Specialty product sales to physician practices and health systems
- January 2025 acquisition of Retina Consultants of America contributing to gross profit expansion
- Share repurchases reducing diluted shares outstanding by 3.0%
- Antitrust litigation settlement gains of $198.6 million
“Cencora's second quarter results reflect the strength of our value proposition as a healthcare services provider and the important role we play in the supply chain, driven by our pharmaceutical distribution footprint and complementary end-to-end services and solutions. We continue to advance our core business and enhance our capabilities, with a focus on elevating our solutions in the markets we serve.”
Cencora CEO, on the earnings call
Forward Guidance & Outlook
Cencora raised its fiscal year 2025 adjusted diluted EPS guidance to a range of $15.70 to $15.95, up from the previous range of $15.30 to $15.60, reflecting stronger U.S. Healthcare Solutions earnings growth and a lower contribution from the International segment. Updated expectations include: adjusted consolidated operating income growth of 13.5% to 15.5% (up from 11.5% to 13.5%); U.S. Healthcare Solutions segment operating income growth of 17.5% to 19.5% (up from 14.5% to 16.5%); International Healthcare Solutions segment revenue growth of 3% to 4% (down from 4% to 5%) with operating income expected to decline 1% to 4% (down from previous guidance of no growth); weighted average diluted shares outstanding of 195.0 to 195.5 million.
COR YoY Financials
COR Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.